Rationale and Challenges for a New Instrument for Remote Measurement of Negative Symptoms DOI Creative Commons
David G. Daniel, Alex S. Cohen, Philip D. Harvey

et al.

Schizophrenia Bulletin Open, Journal Year: 2024, Volume and Issue: 5(1)

Published: Jan. 1, 2024

Abstract There is a broad consensus that the commonly used clinician-administered rating scales for assessment of negative symptoms share significant limitations, including (1) reliance upon accurate self-report and recall from patient caregiver; (2) potential sampling bias thus being unrepresentative daily-life experiences; (3) subjectivity symptom scoring process limited sensitivity to change. These limitations led work group International Society CNS Clinical Trials Methodology (ISCTM) initiate development multimodal instrument. Experts academia industry reviewed current methods assessing domains diminished affect; sociality; verbal communication; (4) goal-directed behavior; (5) Hedonic drives. For each domain, they documented recommended new approaches could potentially be included in The ecological momentary (EMA), which self-reports their condition receipt periodic prompts smartphone or other device during daily routine; direct inference through detection analysis patient’s voice, appearance activity audio/visual sensor-based (eg, global positioning systems, actigraphy) recordings captured by device. developing an instrument resemble NIMH MATRICS was develop battery measuring cognition schizophrenia. Although EMA digital measures are at relatively early stages development/maturity such faces substantial challenges, none them insurmountable.

Language: Английский

COSMIN systematic review and meta-analysis of the measurement properties of the PANSS-6 DOI Creative Commons

Simon Geck,

Maximilian Roithmeier,

Markus Bühner

et al.

European Neuropsychopharmacology, Journal Year: 2025, Volume and Issue: 94, P. 41 - 50

Published: March 9, 2025

Language: Английский

Citations

3
Automated linguistic analysis in speech samples of Turkish-speaking patients with schizophrenia-spectrum disorders DOI
Berat Arslan, Elif Kizilay, Burcu Verim

et al.

Schizophrenia Research, Journal Year: 2024, Volume and Issue: 267, P. 65 - 71

Published: March 22, 2024

Language: Английский

Citations

9
Computational analysis of linguistic features in speech samples of first-episode bipolar disorder and psychosis DOI
Berat Arslan, Elif Kizilay, Burcu Verim

et al.

Journal of Affective Disorders, Journal Year: 2024, Volume and Issue: 363, P. 340 - 347

Published: July 17, 2024

Language: Английский

Citations

8
The Brief negative Symptom Scale (BNSS): a systematic review of measurement properties DOI Creative Commons

Lucia Weigel,

Sophia Wehr, Silvana Galderisi

et al.

Schizophrenia, Journal Year: 2023, Volume and Issue: 9(1)

Published: July 27, 2023

Abstract Background Negative symptoms of schizophrenia are linked with poor functioning and quality life. Therefore, appropriate measurement tools to assess negative needed. The NIMH-MATRICS Consensus defined five domains for symptoms, which Brief Symptom Scale (BNSS) covers. Methods We used the COSMIN guidelines systematic reviews evaluate psychometric data BNSS scale as a Clinician-Rated Outcome Measure (ClinROM). Results search strategy resulted in inclusion 17 articles. When using risk bias checklist, there was generally good reporting structural validity hypothesis testing. Internal consistency, reliability cross-cultural were poorer quality. ClinROM development content showed inadequate results. According updated criteria properties, validity, internal consistency interrater results, while testing Cross-cultural test-retest indeterminate. GRADE approach moderate grade. Conclusions can potentially recommend use concise tool rate symptoms. Due weaknesses certain further validations warranted.

Language: Английский

Citations

14
Exploring depression in people with schizophrenia spectrum disorders: A cross-sectional analysis of the clinical relationship with Positive and Negative Syndrome Scale dimensions DOI Creative Commons
Francesco Bartoli, Angela Calabrese, Federico Moretti

et al.

Brazilian Journal of Psychiatry, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

Objective: Evidence on the relationship between depression and clinical dimensions of schizophrenia remains limited.This cross-sectional study investigated association Positive Negative Syndrome Scale (PANSS) in people with spectrum disorders.Methods: Trained assessors administered PANSS to measure symptoms Calgary Depression for Schizophrenia depression.The overall score related was multiple logistic regression analyses.Results: We included 231 inpatients disorders (mean age: 42.4 (SD: 12.9) years; men: 58.9%; mean score: 82.5 20.1); drug-free or naı ¨ve: 39.3%), including 78 (33.8%) clinically significant depressive symptoms.Depression associated higher (regression coefficient, SE: 0.029, 0.008; p o 0.001) general psychopathology 0.118, 0.023; scores.We found an inverse positive -0.088, 0.028; = 0.002).No negative found.Conclusion: Despite some limitations, our shows that affected by are likely show more but lower symptoms.Additional studies needed explore generalizability findings.

Language: Английский

Citations

5
Schizophrenia Quality of Life Scale and Schizophrenia Quality of Life Scale Revision 4: A Systematic Review of Measurement Properties DOI

Milena Zúñiga Le-Bert,

Max Wiessner,

Sophia Wehr

et al.

Schizophrenia Bulletin, Journal Year: 2024, Volume and Issue: unknown

Published: July 20, 2024

Abstract Background and Hypothesis Schizophrenia is a severe mental disorder that has significant impact on quality of life (QOL). Measuring QOL can offer insights into treatment efficacy areas intervention, highlighting the importance valid tools assessing in people with schizophrenia. Study Design We employed COSMIN systematic review guideline to assess psychometric properties schizophrenia scale (SQLS) its 4th revision, revision 4 (SQLS-R4), as patient-reported outcome measures (PROMs). Results The search yielded 455 papers, 16 were included, 7 for SQLS 9 SQLS-R4. Both scales demonstrated good results risk bias assessment internal consistency convergent validity, SQLS-R4 additionally known-groups validity. For SQLS, PROM development, structural reliability suboptimal. showed suboptimality regarding validity inadequacy cross-cultural responsiveness. updated criteria measurement indicated consistency, reliability, suboptimal while had indeterminate consistency; responsiveness, insufficient When using GRADE approach group, both received very low grade. Conclusions hold potential recommendation rating QOL. Identified weaknesses necessitate further validations.

Language: Английский

Citations

4
Clinician-Reported Negative Symptom Scales: A Systematic Review of Measurement Properties DOI Creative Commons

Lucia Weigel,

Sophia Wehr, Silvana Galderisi

et al.

Schizophrenia Bulletin, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 18, 2024

Negative symptoms of schizophrenia are correlated with reduction normal function and lower quality life. They were newly defined by the NIMH-MATRICS Consensus in 2005, dividing rating tools to assess them into first-generation scales, developed before Consensus, second-generation based on recently introduced definitions.

Language: Английский

Citations

3
Assessment of Negative Symptoms in Schizophrenia: From the Consensus Conference-Derived Scales to Remote Digital Phenotyping DOI Creative Commons
Armida Mucci, Stefan Leucht, Giulia Maria Giordano

et al.

Brain Sciences, Journal Year: 2025, Volume and Issue: 15(1), P. 83 - 83

Published: Jan. 17, 2025

The assessment of negative symptoms in schizophrenia has advanced since the 2006 NIMH-MATRICS Consensus Statement, leading to development second-generation rating scales like Brief Negative Symptom Scale and Clinical Assessment Interview for Symptoms. These address limitations first-generation tools, such as inclusion aspects that are not lack subject's internal experience. However, psychometric validation these is still progress, they yet recommended by regulatory agencies, thus limiting their use clinical trials settings. Complementing traditional methods, remote digital phenotyping offers a novel approach leveraging smartphones wearable technology capture real-time, high-resolution data. Despite potential overcome barriers, challenges remain aligning measures with ratings ensuring data security. Equally important patient acceptance, success relies on willingness patients technologies. This review provides critical overview both assessing symptoms, highlighting future research needs.

Language: Английский

Citations

0
Systematic Review of Self-Assessment Scales for Negative Symptoms in Schizophrenia DOI Creative Commons
Lucie Métivier, Sonia Dollfus

Brain Sciences, Journal Year: 2025, Volume and Issue: 15(2), P. 148 - 148

Published: Jan. 31, 2025

Background/Objectives: Negative symptoms (NSs) significantly impair the outcome of schizophrenia, primarily due to their effect on quality life and resistance pharmacological treatments. Several scales have been developed assess various dimensions NSs, including avolition, anhedonia, alogia, social withdrawal, blunted affect. While observer-rated are most commonly used, self-assessment tools remain underutilized. However, self-assessments offer a promising approach for gaining insights into personal experiences individuals. The objective this review was identify report psychometric properties NSs that relevant both research clinical practice, with focus multiple domains in order support comprehensive evaluations tailored therapeutic strategies. Methods: We conducted an exhaustive literature following PRISMA guidelines self-evaluation evaluate several MEDLINE Web Science databases. COSMIN checklist used methodological each tool. Results: Our identified five scales. Among these, two received Grade A recommendation use or practice: Self-evaluation Symptom (SNS), which assesses Motivation And Pleasure Scale Self-report (MAP-SR), evaluates withdrawal. Conclusions: SNS MAP-SR only sufficient properties, making them reliable practice. Despite development integration settings remains limited, highlighting need increased utilization enhance understanding management these symptoms.

Language: Английский

Citations

0
COSMIN review of the PANSS Marder factor solution and other factor models in people with schizophrenia DOI Creative Commons

Maximilian Roithmeier,

Simon Geck,

Markus Bühner

et al.

Schizophrenia, Journal Year: 2025, Volume and Issue: 11(1)

Published: March 31, 2025

Abstract The Positive and Negative Syndrome Scale (PANSS) is widely used to assess schizophrenia symptoms. Initially designed with three subscales, Marder et al.´s 5-factor-Model (M5M) first proposed in 1997 has been frequently treatment trials, but it never systematically reviewed for its measurement properties. We utilized the COnsensus-based Standards selection of health Measurement INstruments (COSMIN) guideline systematic reviews meta-analytical procedures psychometric properties M5M-PANSS. COSMIN comprises several steps: literature search, risk-of-bias assessments, assessing updated criteria good properties, feasibility aspects grading quality evidence. further assessed goodness fit other PANSS factor models. included 95 publications. M5M-PANSS showed construct validity, “insufficient” structural validity. Evidence domains largely lacking. Among multiple (73) solutions examined confirmatory methods, 5-factor had better model fit. According rules M5M should not be recommended use. Other five-factor models such as one by Wallwork al. 1 warrant evaluation. Nevertheless, composition these was relatively similar, so previously published results disregarded.

Language: Английский

Citations

0